lefamulin pneumonia
Selected indexed studies
- Lefamulin (Xenleta) for community-acquired bacterial pneumonia. (Med Lett Drugs Ther, 2019) [PMID:31599865]
- Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. (Infect Dis Ther, 2021) [PMID:33528794]
- Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia. (Clin Infect Dis, 2020) [PMID:32221520]
_Worker-drafted node — pending editorial review._
Connections
lefamulin pneumonia is a side effect of
Sources
- Lefamulin (Xenleta) for community-acquired bacterial pneumonia. (2019) pubmed
- Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. (2021) pubmed
- Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia. (2020) pubmed
- An overview of lefamulin for the treatment of community acquired bacterial pneumonia. (2020) pubmed
- Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia. (2020) pubmed
- Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia. (2019) pubmed
- Lefamulin. (2012) pubmed
- Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia. (2022) pubmed
- Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. (2021) pubmed
- A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin. (2020) pubmed